GlassScriptPhysician profile
Brook L Mcfadden
NPI 1508903881
$4,514.94
in general payments reported to CMS, 2019-2025
20 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 83% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $87.02 · 2021: $1,159 · 2022: $476 · 2023: $410 · 2024: $164 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309 · Travel and Lodging: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.12 |
| Travel and Lodging | $1,169.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,861.02 | 2021-2025 | Altaviva, Interstim |
| Axonics, INC. | $1,554.54 | 2021-2024 | Axonics, Bulkamid |
| Abbvie INC. | $164.00 | 2019-2025 | |
| Calyxo, INC. | $149.70 | 2025 | Cvac Aspiration System |
| Caldera Medical, INC | $135.31 | 2019 | |
| Merz North America, INC. | $103.66 | 2019 | |
| Boston Scientific Corporation | $102.29 | 2022-2023 | Upsylon |
| Astellas Pharma US INC | $77.54 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2019-2022 | |
| 180 Medical, INC. | $45.20 | 2022 | |
| Olympus America INC. | $42.70 | 2024-2025 | Itind System |
| Urogen Pharma, INC. | $39.28 | 2025 | |
| Astellas Pharma Global Development | $33.10 | 2023 | Veozah |
| Medtronic USA, INC. | $29.56 | 2019-2020 | |
| Roche Diagnostics Corporation | $27.30 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $23.58 | 2023 | |
| Pfizer INC. | $21.23 | 2020 | |
| Exeltis, USA INC. | $19.90 | 2023 | Slynd |
| Coopersurgical, INC. | $18.52 | 2022 | |
| Organon LLC | $18.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brook Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.